DNAP News Just out...
(BSNS WIRE) DNAPrint Hires Master of Stochastic Processes
DNAPrint Hires Master of Stochastic Processes
Business Editors
SARASOTA, Fla.--(BUSINESS WIRE)--Jan. 10, 2001--DNAPrint genomics,
Inc. (Pink Sheets:DNAP) announced today that the company has hired an
accomplished master of stochastic processes to lead its genomics
pattern detection efforts. K. Suresh Chandra, Ph.D. will serve as
Senior Scientist in the Department of Biostatistics.
Dr. Chandra is the inventor of a Markov Sampling Scheme, which was
published in Biometrica in 1992, and which resulted in international
recognition. In all, Dr. Chandra has accumulated 36 years of
university level teaching in statistics, biostatistics and computer
science. Prior to joining DNAPrint genomics, Dr. Chandra served as
Professor of Statistics at the Madras University, Madras, India and
held a joint appointment as an Associate Professor in the Department
of Statistics at the University of Botswana. He has lectured in
Statistics around the world and has been awarded a special U.G.C.
Research scientist status. Dr. Chandra has graduated 11 Ph.D. scholars
as of year 2000 and executed projects focusing on stochastic modeling,
including stochastic models for time series, limit theorems on linear
stochastic models with moving average errors, statistical analysis of
linear stochastic models with polynomial regression components and
Markov sampling schemes for finite populations.
Favorite courses taught by Dr. Chandra over the years include
Measure & Probability Theory, Estimation Theory, Testing of Hypothesis
and Stochastic Process. Dr. Chandra also has a thorough background in
statistical economic analysis, having taught Econometrics and
Mathematical Economics over the years.
Dr. Chandra programs in a variety of languages and has extensive
network of international contacts in the analytical field. At DNAprint
genomics, Dr. Chandra will focus on the development of both supervised
and unsupervised genetic pattern detection algorithms.
Background
Personalized medical products of the near future will use multiple
genetic and environmental markers to match patients with drugs that
are safe and efficacious. Genetic concordance or association studies
are expected to yield the information necessary for the construction
of these products and a process known as inferential haplotyping is
the preferred process by which these studies are conducted. Once
patient data has been produced and condensed using inferential
haplotyping tools, it must be "mined" for the information that will
enable the construction of novel "diagnomics" and/or "prognomics"
products. To date, most have used relatively simple statistical tools
for this mining process. DNAprint genomics was founded based on the
recognition that the major limitation in the genomics field is an
analytical bottleneck, not data volume. In order to quantitatively and
qualitatively relate multi-variate genetic and environmental
parameters to phenotypes (or medical conditions), new pattern
detection algorithms must be developed and employed that specifically
address the needs of the quantitative geneticist/genomicist. DNAprint
genomics is developing these tools, and Dr. Chandra will assist the
company in this endeavor.
About DNAprint genomics
DNAPrint genomics, Inc. is developing complex genetic analytics
and information resources for next generation personalized medicine.
The company's products will provide practitioners of genomic research
and personalized medicine with a comprehensive system for complex
trait dissection and patient classification. DNAPrint genomics Inc.
was founded by a group of scientists with research and commercial
experience in high-level mathematical modeling, programming and
molecular genetics. On November 3, 2000, the company announced that it
had filed its form 8K. The Company has responded to NASD comments and
expects to be trading on the OTCBB in January, 2001.
For additional information about the Company, please visit
www.DNAPrint.com
All statements in this press release that are not historical are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act as amended. Such statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected, including, but not limited to,
uncertainties relating to technologies, product development,
manufacturing, market acceptance, cost and pricing of DNAPrint's
products, dependence on collaborations and partners, regulatory
approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint genomics, Inc. expressly disclaims
any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in DNAPrint's expectations with regard thereto or
any change in events, conditions, or circumstances on which any such
statements are based.
--30--gaa/mi*
CONTACT: DNAPrint genomics, Inc., Sarasota, Fla.
For Scientific inquiries:
Tony Frudakis, Ph.D., 941/351-4543
or
Other inquiries
Richard Craig Hall, 941/341-0136
KEYWORD: FLORIDA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL SOFTWARE EDUCATION
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com |
